Literature DB >> 20665024

Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis.

Kyoung Soo Kim1, Hyun Mi Choi, Yeon-Ah Lee, In Ah Choi, Sang-Hoon Lee, Seung-Jae Hong, Hyung-In Yang, Myung Chul Yoo.   

Abstract

This study was performed to provide evidence, albeit indirectly, as to which matrix metalloproteinases (MMPs), among the gelatinases MMP-2 and MMP-9 and the collagenases MMP-1 and MMP-13, play a more proactive role in the angiogenic process in arthritic joint. Joint fluid was collected from 33 patients with rhuematoid arthritis (RA) and osteoarthritis (OA), and protein (MMPs and vascular endothelial growth factor (VEGF)) levels were measured by ELISA, and the association of MMPs with VEGF was evaluated in joint fluid of patients with RA or OA. The levels of collagenases (total MMP-1 and total MMP-13) and gelatinases (total MMP-2 and total MMP-9) in RA joint fluid were significantly higher than those in OA fluid. Total MMP-9 levels were significantly associated with VEGF levels in RA fluids, but not in OA fluid, while total MMP-13 levels were strongly associated with VEGF levels in both RA and OA fluid. However, total MMP-2 and total MMP-1 levels were not associated with VEGF levels in either RA or OA joint fluid. Our results indirectly suggest that in RA and OA, MMP-9 and MMP-13 may play a more important role in angiogenesis than MMP-2 and MMP-1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665024     DOI: 10.1007/s00296-010-1592-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

Review 1.  Angiogenesis: general mechanisms and implications for rheumatoid arthritis.

Authors:  A J Weber; M De Bandt
Journal:  Joint Bone Spine       Date:  2000       Impact factor: 4.929

2.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Authors:  Y Yoshihara; H Nakamura; K Obata; H Yamada; T Hayakawa; K Fujikawa; Y Okada
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 3.  A review on pro- and anti-angiogenic factors as targets of clinical intervention.

Authors:  Diane Bouïs; Yoka Kusumanto; Coby Meijer; Nanno H Mulder; Geke A P Hospers
Journal:  Pharmacol Res       Date:  2006-02       Impact factor: 7.658

4.  MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes.

Authors:  T H Vu; J M Shipley; G Bergers; J E Berger; J A Helms; D Hanahan; S D Shapiro; R M Senior; Z Werb
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

Review 5.  Matrix metalloproteinases: role in arthritis.

Authors:  Peter S Burrage; Kimberlee S Mix; Constance E Brinckerhoff
Journal:  Front Biosci       Date:  2006-01-01

6.  The role of the matrix metalloproteinases during in vitro vessel formation.

Authors:  M F Burbridge; F Cogé; J P Galizzi; J A Boutin; D C West; G C Tucker
Journal:  Angiogenesis       Date:  2002       Impact factor: 9.596

7.  MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis.

Authors:  I Tchetverikov; H K Ronday; B Van El; G H Kiers; N Verzijl; J M TeKoppele; T W J Huizinga; J DeGroot; R Hanemaaijer
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

8.  Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1.

Authors:  H Wang; J A Keiser
Journal:  Circ Res       Date:  1998-10-19       Impact factor: 17.367

9.  The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis.

Authors:  Takeshi Itoh; Hidetoshi Matsuda; Masatoshi Tanioka; Kenji Kuwabara; Shigeyoshi Itohara; Ryuji Suzuki
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

10.  Taurine chloramine differentially inhibits matrix metalloproteinase 1 and 13 synthesis in interleukin-1beta stimulated fibroblast-like synoviocytes.

Authors:  Kyoung Soo Kim; Eun Kyung Park; Seung Min Ju; Hye-Sook Jung; Jun Soo Bang; Chaekyun Kim; Yeon-Ah Lee; Seung-Jae Hong; Sang-Hoon Lee; Hyung-In Yang; Myung Chul Yoo
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  34 in total

1.  Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13.

Authors:  Kyoung Soo Kim; Yeon-Ah Lee; Hyun Mi Choi; Myung Chul Yoo; Hyung-In Yang
Journal:  Rheumatol Int       Date:  2011-09-13       Impact factor: 2.631

Review 2.  The pathogenic role of angiogenesis in rheumatoid arthritis.

Authors:  Hatem A Elshabrawy; Zhenlong Chen; Michael V Volin; Shalini Ravella; Shanti Virupannavar; Shiva Shahrara
Journal:  Angiogenesis       Date:  2015-07-22       Impact factor: 9.596

3.  Matrine inhibits IL-1β-induced expression of matrix metalloproteinases by suppressing the activation of MAPK and NF-κB in human chondrocytes in vitro.

Authors:  Shijin Lu; Xungang Xiao; Minghua Cheng
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  In vitro study of matrix metalloproteinases 1, 2, 9, 13 and serum amyloid A mRNAs expression in equine fibroblast-like synoviocytes treated with doxycycline.

Authors:  Samaneh Ghasemi; Kamran Sardari; Pezhman Mirshokraei; Hossein Hassanpour
Journal:  Can J Vet Res       Date:  2018-04       Impact factor: 1.310

5.  Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis.

Authors:  Shaowei Wang; Xiaochun Wei; Jingming Zhou; Jing Zhang; Kai Li; Qian Chen; Richard Terek; Braden C Fleming; Mary B Goldring; Michael G Ehrlich; Ge Zhang; Lei Wei
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

6.  Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity.

Authors:  Evan Meszaros; Charles J Malemud
Journal:  Ther Adv Chronic Dis       Date:  2012-09       Impact factor: 5.091

7.  Immunolocalization of MMP-2 and MMP-9 in human rheumatoid synovium.

Authors:  Meng Zhou; Si Qin; Yang Chu; Fengming Wang; Lujun Chen; Yahua Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

8.  Association of dietary intake, medication and anthropometric indices with serum levels of advanced glycation end products, caspase-3, and matrix metalloproteinase-9 in diabetic patients.

Authors:  Elaheh Foroumandi; Sorayya Kheirouri; Rahmat Nosrati; Ramin Ghodsi
Journal:  J Diabetes Metab Disord       Date:  2021-05-02

9.  Silencing matrix metalloproteinase-13 (Mmp-13) reduces inflammatory bone resorption associated with LPS-induced periodontal disease in vivo.

Authors:  Morgana R Guimaraes-Stabili; Marcell Costa de Medeiros; Danuza Rossi; Angelo Constantino Camilli; Cleslei Fernando Zanelli; Sandro Roberto Valentini; Luis Carlos Spolidorio; Keith Lough Kirkwood; Carlos Rossa
Journal:  Clin Oral Investig       Date:  2020-11-02       Impact factor: 3.573

10.  Recent findings on the role of gelatinases (matrix metalloproteinase-2 and -9) in osteoarthritis.

Authors:  Olimpio Galasso; Filippo Familiari; Marco De Gori; Giorgio Gasparini
Journal:  Adv Orthop       Date:  2012-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.